A little girl from Spruce Grove, Alta., has won a lottery being run by a pharmaceutical company to receive a multi-million dollar treatment.
Harper Hanki, who is just over a year old, was diagnosed with spinal muscular atrophy Type 1 (SMA 1) when she was just seven months old.
Harper is missing the primary gene that delivers the protein neurons to all her muscles, including the heart, lungs and esophagus.
Her parents, Amanda and John Hanki, had been desperately trying to raise money for treatment with the drug Zolgensma, which can cost $2.8 million.
They had raised about $272,000, less than a tenth of what they needed, when they received a call this week from Novartis, the company that manufactures the drug.
“We won the baby lottery,” Amber said. “The baby lottery is a lottery that the drug company has put on, and they have committed to giving away 100 free doses throughout the world. And we were selected as one of them.”
“We always crossed our fingers one day that this is how it’d end,” John said.
“Now we can kind of take a big breath and celebrate.”
The “baby lottery” is actually the company’s managed access program that Novartis is running to give away doses of the drug to applicants from all around the world who are under two.
Zolgensma will give Harper the gene she is missing, and although it won’t correct any loss of muscle movement so far, it will stop the spread of SMA.
“It’s awesome,” John said. “There’s still going to be a lot of work ahead for Harper. But this is going to put her on a trajectory to potentially walk one day. That’s what we’re hopeful for.”
The money the family has already raised will go to SMA research, her parents said, or possibly towards helping another Canadian baby with the disease.
“We’re so fortunate and we would love to see everyone benefit from it,” Amanda said.
Harper will go to Calgary to get testing done at the beginning of November, and then is set to receive Zolgensma, also in Calgary, in December. Her family says they believe she will be one of the first Albertans to receive it.
“We know right now Harper is living on borrowed time, and we can’t wait to see what she does with it,” Amanda said.
Harper had previously been receiving Spinraza, a drug that is administered by injection every four months, with each dose carrying a price tag of $125,000.
Zolgensma is a one-time treatment. It has not yet been approved by Health Canada.
Spinal muscular atrophy (SMA) Type 1 is a rare disorder that affects about 1 in 6,000 babies and causes muscles to waste away. Most die of respiratory issues before their second birthday.
–With files from Jessica Robb, Su-Ling Goh and Amy Judd, Global News
Comments